Foghorn Therapeutics Inc.
FHTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $8 | $8 | $6 | $3 |
| % Growth | 7.9% | 27% | 108.4% | – |
| Cost of Goods Sold | $20 | $1 | $0 | $0 |
| Gross Profit | -$12 | $7 | $6 | $3 |
| % Margin | -145.3% | 88.1% | 100% | 100% |
| R&D Expenses | $20 | $21 | $22 | $21 |
| G&A Expenses | $7 | $7 | $7 | $6 |
| SG&A Expenses | $7 | $7 | $7 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$20 | $0 | $0 | $0 |
| Operating Expenses | $7 | $28 | $29 | $27 |
| Operating Income | -$19 | -$21 | -$23 | -$24 |
| % Margin | -226.9% | -279.2% | -385% | -840.5% |
| Other Income/Exp. Net | $3 | $3 | $4 | $5 |
| Pre-Tax Income | -$16 | -$18 | -$19 | -$20 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$16 | -$18 | -$19 | -$20 |
| % Margin | -194.4% | -237.3% | -316.4% | -682.9% |
| EPS | -0.25 | -0.28 | -0.3 | -0.31 |
| % Growth | 10.7% | 6.7% | 3.2% | – |
| EPS Diluted | -0.25 | -0.28 | -0.3 | -0.31 |
| Weighted Avg Shares Out | 63 | 63 | 63 | 63 |
| Weighted Avg Shares Out Dil | 63 | 63 | 63 | 63 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $3 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$15 | -$17 | -$22 | -$23 |
| % Margin | -183.9% | -225.4% | -371.1% | -813.9% |